Why brain tumor cells stop responding to temozolomide
Original title: EGFR/TBK1-dependent mitochondrial quality control contributes to acquired resistance to temozolomide.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This was only done in tumor cells grown in a dish.
The short version
Lab work shows one way tumor cells learn to survive a common chemo drug.
What was studied. Researchers grew human brain tumor cells in a dish and treated them with temozolomide: A chemotherapy taken as a capsule, used for some brain tumors. Your team checks your blood counts while you are on it. See the glossary. They tracked the cells over time as the drug slowly stopped working. They also used gene tools and drugs to block single steps inside the cells.
What they found. The cells first went through a burst of stress. Then they cleaned out and recycled their damaged power parts, called mitochondria. Two proteins, EGFR and TBK1, switched that recycling on. The recycling was a needed step before the drug-resistant cells took over.
What this means, and what it doesn't
What it could mean: temozolomide: A chemotherapy taken as a capsule, used for some brain tumors. Your team checks your blood counts while you are on it. See the glossary often stops working over time, and this points to one reason why. If this recycling step could be blocked, the drug might keep working longer. That is only an idea right now. It has not been tried in people.
What it doesn't mean: This is not a new treatment, and it is not a cure. The work was done only on cells in a dish. No person was treated or helped in this study. It is a long way from anything a doctor can offer. Many lab findings like this never work out in people.
Source: PubMed, November 2, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.